Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers
NCT ID: NCT04699305
Last Updated: 2025-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2019-02-14
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence
NCT04899466
Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh
NCT01769144
Clinical Registry Collecting Real World Evidence on Wound Care Treatments
NCT06328010
Clinical Trial of CSMed Wound Dressing for Radiation Dermatitis
NCT06001463
Effect Of Resistive Capactive Electrical Transfer Therapy In Difficult-to-heal Wounds
NCT05953935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ActiGraft
Whole blood clot (WBC) gel
ActiGraft
Whole blood clot (WBC) gel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ActiGraft
Whole blood clot (WBC) gel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has an exuding cutaneous wound
* Subject agrees to the use of his health data, including photos of his wound in analysis and publications
* Subject/LAR must be able to read and understand English and/or Spanish
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RedDress Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Sirota
Role: STUDY_DIRECTOR
RedDress Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wound Care Experts
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Naz Wahab, M.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Williams M, Davidson D, Wahab N, Hawkins J, Wachuku CD, Snyder R. Innovative treatment utilizing an autologous blood clot for diabetic foot ulcers. Wounds. 2022 Jul;34(7):195-200. doi: 10.25270/wnds/21089.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.